234 related articles for article (PubMed ID: 35875870)
1. Discovery of a Transferrin Receptor 1-Binding Aptamer and Its Application in Cancer Cell Depletion for Adoptive T-Cell Therapy Manufacturing.
Cheng EL; Cardle II; Kacherovsky N; Bansia H; Wang T; Zhou Y; Raman J; Yen A; Gutierrez D; Salipante SJ; des Georges A; Jensen MC; Pun SH
J Am Chem Soc; 2022 Aug; 144(30):13851-13864. PubMed ID: 35875870
[TBL] [Abstract][Full Text] [Related]
2. Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.
Cardle II; Cheng EL; Jensen MC; Pun SH
Acc Chem Res; 2020 Sep; 53(9):1724-1738. PubMed ID: 32786336
[TBL] [Abstract][Full Text] [Related]
3. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?
Palen K; Zurko J; Johnson BD; Hari P; Shah NN
Cytotherapy; 2021 Nov; 23(11):985-990. PubMed ID: 34538575
[TBL] [Abstract][Full Text] [Related]
4. Better by design: What to expect from novel CAR-engineered cell therapies?
Luginbuehl V; Abraham E; Kovar K; Flaaten R; Müller AMS
Biotechnol Adv; 2022 Sep; 58():107917. PubMed ID: 35149146
[TBL] [Abstract][Full Text] [Related]
5.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
6. Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas.
Johnson PC; Abramson JS
Leuk Lymphoma; 2020 Nov; 61(11):2561-2567. PubMed ID: 32611216
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
Abramson JS; Lunning M; Palomba ML
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
[TBL] [Abstract][Full Text] [Related]
8. Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing.
Qayed M; McGuirk JP; Myers GD; Parameswaran V; Waller EK; Holman P; Rodrigues M; Clough LF; Willert J
Cytotherapy; 2022 Sep; 24(9):869-878. PubMed ID: 35718701
[TBL] [Abstract][Full Text] [Related]
9. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
10. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
Teoh J; Brown LF
Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
[TBL] [Abstract][Full Text] [Related]
11. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
12. [Engineering memory-rich CAR-T cells by a piggyBac transposon system].
Yagyu S
Rinsho Ketsueki; 2023; 64(5):418-426. PubMed ID: 37271534
[TBL] [Abstract][Full Text] [Related]
13. Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells.
Stroncek DF; Ren J; Lee DW; Tran M; Frodigh SE; Sabatino M; Khuu H; Merchant MS; Mackall CL
Cytotherapy; 2016 Jul; 18(7):893-901. PubMed ID: 27210719
[TBL] [Abstract][Full Text] [Related]
14. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering.
Michels KR; Sheih A; Hernandez SA; Brandes AH; Parrilla D; Irwin B; Perez AM; Ting HA; Nicolai CJ; Gervascio T; Shin S; Pankau MD; Muhonen M; Freeman J; Gould S; Getto R; Larson RP; Ryu BY; Scharenberg AM; Sullivan AM; Green S
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918221
[TBL] [Abstract][Full Text] [Related]
15. Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications.
Blache U; Weiss R; Boldt A; Kapinsky M; Blaudszun AR; Quaiser A; Pohl A; Miloud T; Burgaud M; Vucinic V; Platzbecker U; Sack U; Fricke S; Koehl U
Front Immunol; 2021; 12():658314. PubMed ID: 34012442
[TBL] [Abstract][Full Text] [Related]
16. Generation of Redirected Engineered Human Chimeric Antigen Receptor (CAR) T Cells.
Bunse M; Höpken UE
Methods Mol Biol; 2022; 2521():67-83. PubMed ID: 35732993
[TBL] [Abstract][Full Text] [Related]
17. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
18. Opportunities and obstacles for the melanoma immunotherapy using T cell and chimeric antigen receptor T (CAR-T) applications: a literature review.
Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori H; Mansoori Y; Salahi A; Nikfar G; Tavassoli A; Behmard E; Moravej A; Ghasemian A
Mol Biol Rep; 2022 Nov; 49(11):10627-10633. PubMed ID: 35715610
[TBL] [Abstract][Full Text] [Related]
19. Approaches of T Cell Activation and Differentiation for CAR-T Cell Therapies.
Schwab RD; Bedoya DM; King TR; Levine BL; Posey AD
Methods Mol Biol; 2020; 2086():203-211. PubMed ID: 31707678
[TBL] [Abstract][Full Text] [Related]
20. Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics.
Elavia N; Panch SR; McManus A; Bikkani T; Szymanski J; Highfill SL; Jin P; Brudno J; Kochenderfer J; Stroncek DF
Transfusion; 2019 May; 59(5):1755-1764. PubMed ID: 30973976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]